Company / Total Debt
Viridian Therapeutics, Inc.\DE Total Debt History
FY2017-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Total Debt
$20.6M
FY2024
5-year range
$0 / $20.6M
FY2020-FY2024
Trend
+1.9%
vs FY2023
Sector context
#78 of 83
Health Care
What the data says
Among 83 Health Care companies, Viridian Therapeutics, Inc.\DE is in the top 6% for total debt. Total Debt has increased for 3 consecutive years, from $0 in FY2021 to $21M in FY2024.
Based on SEC 10-K filings.
$21M in FY2024 with a 5-year CAGR of +21.8%.
Increased from $5M to $21M over the past 2 years.
Health Care sector context is included.
Total Debt over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- +21.8%
- 10-Year CAGR
- -
Sector benchmark
Top 6% in Health CareTop 6% of 83This company $20.6M Sector average $6.2B
▼
-99.7% below sector average
Key checks
Key Insights
- 5-year CAGR of +21.8%, indicating consistent growth.
- In FY2024, total debt increased 1.9% year-over-year.
- Ranks #78 out of 83 companies in the Health Care sector.
- Lowest total debt in the period was in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 1.11 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Total DebtValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | $20.6M | +1.9% |
| FY2023 | $20.2M | +335.0% |
| FY2022 | $4.6M | - |
| FY2021 | $0 | - |
| FY2020 | - | - |
| FY2019 | $7.7M | -23.3% |
| FY2018 | $10.0M | +0.0% |
| FY2017 | $10.0M | - |
| FY2016 | - | - |
As of FY2024 · SEC 10-K · Updated Jun 30, 2026